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Background: Pulmonary neuroendocrine tumors (Pulmonary NETs) include a wide spectrum of tumors, from the
low-grade typical carcinoid (TC) and the intermediate-grade atypical carcinoid (AC), to the high-grade large-cell
neuroendocrine carcinoma (LCNEC) and the small-cell carcinoma (SCLC). Epithelial Mesenchymal Transition (EMT) is
a process initially recognised during several critical stages of embryonic development, which has more recently
been implicated in promoting carcinoma invasion and metastasis. The initial stage of the EMT process begins with
the deregulation of adhesion molecules, such as E-cadherin, due to transcriptional repression carried out by factors
such as Snail family members, Twist and Foxc2.
Methods: Immunohistochemistry for EMT markers and E-cadherin/ β-catenin complex in 134 patients with pulmonary
NETs between 1990 – 2009. Analysis of potential associations with clinicopathological variables and survival.
Results: Pulmonary NETs of high malignant potential (LCNEC and SCLC) had reduced expression of the adhesion
molecules and high level expression of transcriptional repressors (Snail1, Snail2, Twist and Foxc2). Snail high
expression levels and the loss of E-cadherin/β-catenin complex integrity had the strongest negative effect on the
five-year survival rates. E-cadherin/β-catenin complex integrity loss independently predicted lymph node involvement
and helped in Atypical Carcinoid (AC) vs Typical Carcinoid (TC) differential diagnosis. Importantly, among the TC group,
the loss of E-cadherin/β-catenin complex integrity identified patients with an adverse clinical course despite favourable
clinicopathological features.
Conclusion: The immunohistochemical determination of E-cadherin/β-catenin complex integrity loss and EMT markers
in the clinical setting might be a potential useful diagnostic and prognostic tool especially among the TC patients.
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Pulmonary Neuroendocrine Tumors (Pulmonary NETs)
express differential characteristics of neuroendocrine cells
scattered among epithelial cells [1,2]. They represent a
broad clinico-pathologic spectrum and have variable
morphologic features and biologic behaviours. Pulmon-
ary NETs account for 20% of lung carcinomas and their
incidence has increased significantly in recent decades* Correspondence: gonzalezvictoria@uniovi.es
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unless otherwise stated.(6% per year), due in part to early diagnosis imaging;
however, most of them are found accidentally [3-5].
The current classification of the World Health
Organization (WHO), 2004, for pulmonary NETs, pro-
posed by Travis W. D. et al. [6], defines four histological
types based on conventional morphological data (organoid
growth pattern, mitotic index and necrosis) and immuno-
histochemical features, with different prognostic and
therapeutic implications: 1. Typical Carcinoid (TC): “well
differentiated neuroendocrine tumors of low malignant
potential”. 2. Atypical Carcinoid (AC), “well-differentiated
neuroendocrine tumors of intermediate malignant poten-
tial, 3. and 4. Large Cell Neuroendocrine CarcinomaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathologic features of the studied patients
and their tumors (N = 134)
N %
Age (Mean 56 years)
≤ 56 years 61 45.5
> 56 years 73 54.5
Gender
Female 45 33.6
Male 89 66.4
Lymph nodes status
Free 84 62.7
Affected 45 33.6
Unknow 5 3.7
Tumor size (Mean 3 cm)
Small ≤3 cm 80 59.7
Big >3 cm 54 40.3
Necrosis
Negative 68 50.7
Positive 44 32.8
Unknow 22 16.4
Mitotic index
≤2 mitosis 64 47.8
3-20 mitosis 11 8.2
>20 mitosis 35 26.1
Unknow 24 17.9
Diagnosis WHO
TC 66 49.3
AC 10 7.5
LCNEC 18 13.4
SCLC 40 29.9
Tobacco consumption
Non-smorker 52 38.8
Smorker 82 61.2
Treatment
Surgery 98 73.1
Chemotherapy 57 42.5
Radiotherapy 31 23.1
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poorly differentiated neuroendocrine tumors of high ma-
lignant potential.
Epithelial-to-Mesenchymal Transition (EMT) is a revers-
ible process of cellular changes including loss of apico-
basal polarity [7], disintegration of tight junctions [8] and
acquisition of a variable cell shape that facilitates cell
movement and metastasis [9,10]. Reduction of cell–cell
adherence is achieved via the transcriptional repression
and delocalization of cadherins [11,12]. Members of the
Snail family (Snail1 and Snail2), induce EMT by repressing
the transcription of E-cadherin [13,14], similarly to the
mechanism of action of Twist [15,16], and indirectly Foxc2
[17]. Moreover, when E-cadherin is deregulated, β-catenin
is detached from the cell membrane and translocated to
the nucleus to participate in EMT signalling events [18].
During EMT, another process called “cadherins switch”
takes place. It has been described as an increase in
N-cadherin expression (neural cadherin), with or without
decrease of E-cadherin [19,20].
In 2010, our group showed evidence that Snail expres-
sion is associated with pulmonary NETs malignancy
potential [21]. In the present study, we analyze other
EMT markers in a larger cohort of patients with pul-
monary NETs, their relation with E-cadherin/β-catenin
complex expression and their associations with molecu-
lar and relevant clinicopathologic features.
Methods
Patients and samples
134 surgical pulmonary NETs samples (diagnosed be-
tween 1990 and 2009) were obtained from the Pathology
Unit of the Hospital Universitario Central de Asturias, the
Instituto Nacional de Silicosis and the Centro Médico de
Asturias. Informed consent approved by the Hospital
Ethical Board (Comité ético de investigación clínica
regional del Principado de Asturias) for sample banking
and research use was obtained from patients at the time
of the surgery. The series included 66 TCs, 10 ACs, 18
LCNECs and 40 SCLCs transbronchial biopsies. Clini-
copathologic features for the entire cohort of patients
are summarized in Table 1.
The diagnosis of neuroendocrine tumors was based
on morphologic criteria according to the most recent
World Health Organization classification and on immu-
nophenotypical findings, including reactivity to neuroen-
docrine markers (synaptophysin and chromogranin A)
as well as the evaluation of proliferation marker Ki67
(Additional file 1).
Tissue microarrays construction
Tissues obtained from surgical specimens were fixed in
10% formaldehyde and paraffin embedded, and stained
with H&E. Representative tumor regions were selectedto make four tissue microarrays (TMA) containing three
tissue cores from each of the 134 samples. Microarrayer
(Beecher Instruments, Sun Prairie, WI, USA) was used.
After five minutes at 60°C, the TMA blocks were cut in
4 μm-thick sections for immunohistochemical techniques.
Immnunohistochemistry
The automated system DISCOVERY® (Ventana Medical
System, Tuczon, AZ, USA) was used to carry out the
immunohistochemical protein detection of interest.
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(Ventana Medical System, Tuczon, AZ, USA) for 20 -
minutes. Antigen retrieval was done by heating citrate
buffer solution (pH 6.5) and HCl-Tris buffer solution
(pH 9.0). Non-specific antibody binding was blocked
using casein (Antibody block®, Ventana Medical System,
Tuczon, AZ, USA) for 20 minutes. Endogenous peroxid-
ase activity was blocked with H2O2 solution (Inhibitor®,
Ventana Medical System, Tuczon, AZ, USA) for four mi-
nutes. Samples were incubated with primary antibody at
37°C: polyclonal anti-Snail1 (Abcam 17732, Cambridge,
UK) (1:300 dilution); polyclonal anti-Snail2 (Abcam
Cambridge, UK) (1:100 dilution); polyclonal anti-Twist
(Abcam Cambridge, UK) (1:1000 dilution); polyclonal
anti-Foxc2 (ABR Affinity Bioreagents, Colorado, USA)
(1:600 dilution), monoclonal anti-E-cadherin (Dako,
Denmark) (1:100 dilution) and monoclonal anti-β-catenin
(Sigma, Missouri, USA) (1:1000 dilution), monoclonal
anti-N-cadherin (Becton Dickinson, NJ, USA) (1:200 dilu-
tion) and monoclonal anti-Vimentin (Ventana Medical
System, Tuczon, AZ, USA) (1:100 dilution).
The slides were incubated with the secondary antibody
(OmniMap® Ventana medical System, Tuczon, AZ, USA)
for 30 minutes at room temperature. Subsequently, the
samples were visualized with DAB (3-3’-Diaminoben-
zidine) (Ventana Medical System, Tuczon, AZ, USA).
Finally, samples were counterstained with hematoxylin
(Ventana Medical System, Tuczon, AZ, USA), dehy-
drated and mounted in Entellan® (Merck, Germany). The
sections were studied and photographed under a light
microscope (20× objective, Nikon - Eclipse 80i, Japan).
The healthy respiratory epithelium was taken as posi-
tive control for E-cadherin and β-catenin and as negative
control for all transcription factors implicated in EMT.
The protein expression levels were evaluated by two
independent observers, AA and JAG. The interobservers
and intraobserver reproducibility of IHC staining scoring
was determined by Kappa statistics for all markers
assessed by two independent observers (Additional file 2).
In case of discrepancy a consensus was reached with the
help of a third observer (MVG). Two parameters were
taken into account: immunohistochemical signal intensity
(in a 0-3 point scale) and the percentage of positive tumor
cells in a 20× field (1.2 mm). The product of both parame-
ters rendered a score for each specimen. For statistical
purposes, the tumors were divided into two groups, taking
the median score value for each marker as a cut-off point.
For both cadherins and β-catenin, their presence/
absence in the cell membrane was recorded. We created
a variable reflecting the integrity of the E-cadherin/β-
catenin complex in the cellular membrane, which included
two categories: retained integrity (both molecules showing
a membranous pattern) and lost integrity (expression of
at least one of them not observed in the membrane).For EMT markers (Snail1, Snail2, Twist and Foxc2) only
nuclear immunostaining signal was considered and
Vimentin expression was assessed as present vs. absent
staining.
Statistical analysis
The experimental results distributed among the different
clinical groups of tumors were tested for significance
employing the χ2 test (with Yates’ correction, when
appropriate) or logistic regression models to evaluate the
independent effect (Odds Ratio) of transcription factors
on a given clinicopathological or molecular feature.
Survival curves were calculated using the Kaplan-Meier
product limit estimate. Differences between survival times
were analyzed by the log-rank method and the Hazard
Ratio was calculated by univariate Cox regression analysis.
Multivariate Cox proportional hazard models (forward
Wald method) were used to examine the relative impact
of those statistically significant variables in univariate
analysis. All statistical analysis was carried out with the
software package SPSS 20.0 (SPSS, Inc., Chicago, IL). All
tests were two-sided and p < 0.05 values were considered
statistically significant.
Results
The results are reported following the REMARK guide-
lines (REporting recommendations for tumor MARKer
prognostic studies) [22].
Associations between molecular findings and
clinicopathologic features
Expression of adhesion molecules (E-cadherin, β-catenin),
was detected in the healthy epithelial tissue (Figure 1B, 1C)
with a faint positive N-cadherin signal (Figure 1H, inset).
In tumours, reduced expression of E-cadherin and β-
catenin was observed and this was associated with high
malignant potential tumours (p = 0.0001 for all). Moreover,
E-cadherin and β-catenin were localized more frequently
in the cytoplasm, so that E-cadherin/β-catenin complex
loss of integrity was associated with LCNECs and SCLCs
(p = 0.0001). Regarding N-cadherin, the signal intensity
decreased with increasing tumor malignancy (Figure 2).
In addition, the integrity of E-cadherin/β-catenin com-
plex was lost in the unfavourable categories of these clini-
copathologic variables: tumor size (>3 cm) (p = 0.006),
presence of lymph node metastasis (p = 0.0001), presence
of necrosis (p = 0.0001), higher mitotic index (p = 0.0001)
and tobacco consumption (p = 0.0001).
In 39 cases β-catenin was not found at the membrane. 8
of these cases displayed a nuclear localization, correspond-
ing to 6 SCLC, 1 LCNEC and 1 AC (Additional file 3).
None of the transcriptional repressors (Snail1, Snail2,
Twist and Foxc2) were expressed in the healthy respira-
tory epithelium (Figure 1D-1G). In tumors, all of them
Figure 1 Immunohistochemistry of EMT markers in healthy respiratory epithelium. A: H&E, B: E-cadherin, C: β-catenin, D: Snail1, E: Snai2,
F: Twist, G: Foxc2, H: N-cadherin (inset image, shows weak positive N-cadherin signal) and I: Vimentin. 50 μm scale bar (200X).
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tumors (p = 0.0001 each) (Figure 3), with necrosis
(p <0.05 each), a high mitotic index (p <0.001 each), in
patients with lymph node involvement (p <0.01 each), and
in smokers (p <0.01 each). In addition, larger tumors hadFigure 2 Immunohistochemistry of E-cadherin, β -catenin and N-cadh
50 μm scale bar (200X). Consecutive tissue sections of each NET type are
Ecadherin/β-catenin signal.higher Snail1 expression (p = 0.009). The mesenchymal
marker Vimentin was expressed at higher levels in high
grade tumors (p = 0.012).
Among Snail1, Snail2, Twist, Foxc2 and E-cadherin/β-
catenin complex integrity, the following factors wereerin protein expression (rows) in pulmonary NETs (columns)
shown for each marker. Arrows, disrupted membranous pattern for
Figure 3 Immunohistochemistry of Snail1, Snail2, Twist and Foxc2 protein expression (rows) in pulmonary NETs (columns) 50 μm scale
bar (200X).
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SNAIL2 (OR: 4.9; 95% CI: 1.70–14.60, p = 0.003),
TWIST (OR: 3.10; 95% CI: 1.11–8,64, p = 0.031), and
E-cadherin/β-catenin complex integrity (OR: 5.64; 95% CI:
1.78–17.87, p = 0.003).
Mitotic index and tobacco consumption independ-
ently predicted lymph node involvement when they
were included along with tumor size and necrosis in
a logistic regression model (OR: 11.08; 95% CI: 1.08-
113.95, p = 0.043 and OR: 6.36; 95% CI: 1.12-36.06,
p = 0.037, respectively).Differential diagnosis between Pulmonary NETs subtypes
With the aim of identifying molecular variables useful in
tumor subtypes discrimination, comparisons of each
variable were made between TC vs. AC and LCNECs vs.
SCLCs. We found significant differences in the patterns
of different adhesion molecules, which were more fre-
quent in TCs vs. ACs: membrane pattern of E-cadherin
(p = 0.0001), of β-catenin (p = 0.032), of N-cadherin
(p = 0.011) and E-cadherin/β-catenin complex integrity
retained (p = 0.009). Figure 2 illustrates these findings
regarding ACs vs TCs. With respect to N-cadherin,
half ACs cases expressed low levels, as the one shown
in the figure. Consecutive tissue sections for each marker
were included.Among the variables that differentiated SCLCs from
LCNECs, high Snail1 (p = 0.0001), high Snail2 (p = 0.0001)
and high Twist (p = 0.001), as well as reduced E-cadherin
(p = 0.001), β-catenin cytoplasmic expression (p = 0.0001)
and cytoplasmic pattern of N-cadherin (p = 0.001), were
more frequent in SCLC vs. LCNEC.Molecular findings correlations
As expected, we observed an inverse correlation between
E-cadherin and Snail1 (p = 0.02) or Snail2 protein ex-
pression levels (p = 0.001). In addition, the E-cadherin
localization in the membrane correlated when EMT
markers low expression: Snail1 (p = 0.0001), Snail2 (p =
0.0001), Twist (p = 0.013) and Foxc2 (p = 0.002).
In a logistic regression model including Snail1, Snail2,
Twist and Foxc2, high Snail1 expression levels conferred
an elevated risk of losing complex integrity (OR 4.91;
95% CI: 1.909 – 13.348, p = 0.002), and an elevated risk
of finding N-cadherin in the cytoplasm (OR 5.9; 95% CI:
2.002 – 17.916, p = 0.001). A similar model rendered
Twist as the transcription factor whose expression
correlated with N-cadherin expression (OR 2.8, 95% CI:
1.24 – 6.414, p = 0.016).
Vimentin expression was significantly correlated with
increased expression of Snail1 (p = 0.03) and Snail2
(p = 0.019) but not with Twist and Foxc2 expression.
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switch”. N-cadherin expression not only did not increase
in malignant tumors but, on the contrary, it decreased
in parallel to E-cadherin expression.
Survival analysis
The mean follow-up time for this cohort was 90 months,
with a range of 12-242 months and the five year survival
rate was 53.8%. The five year cumulative survival rate
for patients stratified by NET morphologic subtypes was
significantly higher in TC and AC [87.6% and 62.5%,
respectively] than in the LCNECs and SCLC [24.2% and
20.7%, respectively] (Figure 4).
A negative impact on patient survival was found for the
following clinicopathological variables: gender (male), age
(>56 years), node involvement, tobacco consumption and
high mitotic index. Among these, tobacco consumption
presented the highest Hazard Ratio (11-fold risk of death
of disease). Regarding molecular variables, those with a
negative impact on survival were: altered E-cadherin/β-
catenin complex (Figure 5A), high Snail1 (Figure 5B),
Snail2 (Figure 5C) and Foxc2 levels, (Figure 5D). Among
them, Snail1 presented the highest Hazard Ratio (7-fold
risk of death of disease) (Table 2).
In multivariate survival analysis (Cox), we included the
following variables, which were significant in univariate
analysis: age, gender, tobacco consumption, diagnosis,
lymph node involvement, mitotic index and all molecu-
lar variables regarding protein expression. Age, diagnosis
and tobacco consumption showed an independent prog-
nostic value (Table 2).Time (months)
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Figure 4 Cumulative Kaplan-Meier survival curves stratified accordingDifferences in survival between TCs
Typical carcinoid (TC) tumors have better prognosis
than other pulmonary NETs. However, some of these
patients follow an unfavourable clinical course, unpre-
dictable from the available clinicopathological features,
including lymph node status. In our series, only 1/5
patients with an unfavourable course had affected nodes.
With the aim of finding some molecular factors that
could help in the identification of this subgroup, we per-
formed a survival analysis on the TC series. The mean
follow-up time for this group was 106 months (range
14-242 months) and 92.4% had tumour free lymph
nodes. There was a difference in ten year survival rates
when these patients were stratified by E-cadherin/β-
catenin complex integrity (94% complex preserved vs
56% complex altered p = 0.03) (Figure 6). This result
could provide tools that assist the clinician to identify
patients with TC of poor prognosis.
Discussion
Pulmonary NETs are considered a rare pathology.
Despite our knowledge about their biology and genetics
has increased in the past years, the mechanisms or
pathways involved in the progression and metastasis
still remain unclear. One of the most studied mecha-
nisms of tumor cell spread is the Epithelial Mesenchy-
mal Transition (EMT), which has been observed in
breast [23], ovarian, colon [24] and esophageal [25]
cancer models. The first step in EMT process is the loss
of E-cadherin/β-catenin complex. Accordingly, in our
study we observed that the E-cadherin/β-catenin complex250200
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Figure 5 Cumulative Kaplan–Meier survival curves stratified according to: A: E-cadherin/β-catenin complex, B, Snail1 protein expression
levels, C: Snail2 protein expression levels and D: Foxc2 protein expression levels.
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with a linear pattern and a high level expression of both
molecules in the normal tissues used as controls. Such
expected observations are consistent with this complex’s
function in mediating intercellular adherens junctions,
maintaining the integrity of the epithelium [26]. However,
this pattern was lost in tumors, where a cytoplasmic
localization of these molecules was observed. Moreover,
reduced membrane expression levels of E-cadherin and
β-catenin correlated with tumors of higher malignancy, of
greater size, higher mitotic index and with necrosis.
Importantly, loss of complex integrity was the molecular
factor conferring a higher risk of lymph node involvement
(5,6-fold) in an independent fashion. These results, in
concordance with other studies [27,28], support the
notion of CDH1 gene functioning as an invasion suppressor
gene in this type of tumor.Although it was not our initial focus, we considered
the β-catenin localization when absent from the cell
membrane. It is known that β-catenin has two import-
ant roles in tumorigenesis: through its interaction with
E-cadherin at the cell surface it allows the formation
of intercellular adherens junctions, mediating contact
inhibition and suppressing tumor invasion. However,
β-catenin is also a key mediator in the Wnt signalling
pathway which regulates cell proliferation and differen-
tiation [29,30].
Activation of the Wnt pathway leads to a rise in
β-catenin levels in the cytoplasm, and its accumulation in
the nucleus. There, it activates the TCF/LEF transcription
factors, which act on a number of Wnt target genes,
including c-Myc, tcf1 and cyclinD1. The role of the Wnt/
β-catenin pathway has been established in a number of
tumor types, particularly in the development of colorectal
Table 2 Results of univariate and multivariate Cox
survival analysis
Univariate Cox analysis Sig. HR 95% CI
Gender (male) 0.001 4.43 1.86 10.58
Age (>56 years) 0.005 2.61 1.03 1.08
Lymph Node (affected) 0.000 6.63 3.38 12.99
Mitotic index (high) 0.000 4.15 2.51 6.88
Tobacco consumption 0.000 11.18 3.44 36.31
Diagnosis 0.000 2.23 1.69 2.94
Necrosis (present) 0.000 8.95 3.6 22.24
Snail1 (high expression) 0.000 6.96 3.17 15.28
Snail2 (high expression) 0.000 5.2 2.57 10.54
Foxc2 (high expression) 0.039 1.85 1.01 3.38
E-cadherin (low expression) 0.001 3.04 1.54 6.03
β-catenin (low expression) 0.052 1.88 1 3.56
E-cadherin/β-catenin complex integrity (lost) 0.000 5.78 2.27 14.72
Multivariate Cox analysis
Age (>56 years) 0.029 1.029 1 1.06
Diagnosis 0.006 1.634 1.15 2.33
Tobacco consumption 0.024 4.839 1.23 18.99
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limited knowledge of its role in mesenchymal tumors.
Interestingly, in our pulmonary NET series, 31 cases
displayed cytoplasmic β-catenin signal and in 8 additional
cases a nuclear signal was detected. Taken together, most
of these were SCLC samples (23/39) (p < 0.0001), sug-
gesting a possible contribution of cytoplasmic/nuclear
β-catenin to pulmonary NET aggresiveness. This obser-
vation merits further studies to elucidate the potentialTime (months)
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Figure 6 Cumulative Kaplan–Meier survival curves stratified of patientsinvolvement of the Wnt signaling pathway to pulmon-
ary NET development.
With the purpose of deepening into the knowledge of
the molecular events associated with the of E-cadherin/
β-catenin complex loss of integrity in pulmonary NETs,
we evaluated the expression of transcription factors,
Snail1, Snail2, Twist and Foxc2, that have been shown to
be involved in EMT. Healthy respiratory epithelium
showed negative immunostaining for these factors.
However, pulmonary NETs showed Snail1 and Snail2
expression, with an inverse correlation with E-cadherin
expression consistent with their role as transcriptional
repressors of E-cadherin [14,31]. Irrespective of the
other factors’ expression levels, high Snail1 protein
nuclear expression conferred a higher risk of losing
E-cadherin/β-catenin complex integrity in the mem-
brane and a higher risk of finding N-cadherin in the
cytoplasm. Likewise, Twist expression correlated with
N-cadherin expression.
The observation of an association between Vimentin
and Snail1 or Snail2 high expression confirms the results
described by Kokkinos et al. as a key event in the
process of EMT in vitro and in vivo [32].
Importantly, Snail1, Snail2, Foxc2, E-cadherin, N-
cadherin, β-catenin expression and complex integrity
all showed an impact on disease prognosis, with high Snail
expression and loss of complex integrity being the factors
with strongest effect in the five-year survival rates (7-fold
and 6-fold higher risk of death of disease, respectively).
Among clinicopathological variables, diagnosis, age and
tobacco consumption were the factors with independent
prognostic value. These results are in concordance with
those by Travis et al [33].250200
Altered complex
Preserved complex
E-cadherin/  -catenin
complex
p= 0,03
diagnosed with TC, according to E-cadherin/β-catenin complex.
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opment, carcinogenesis and metastasis is characterized
by a switch in classical cadherins yielding high levels of
N-cadherin (CDH2 gene) regardless of E-cadherin levels
(CDH1 gene) [34]. In our series, N-cadherin expression
was detected as a faint signal in some epithelial healthy
cells as a reminiscence of its expression during embry-
onic development [35]. In tumors, N-cadherin protein
expression did not increase with malignancy, on the
contrary, it was expressed at high levels in TCs and
decreased in parallel with E-cadherin expression. Elevated
protein levels of both cadherins were observed more
frequently in tumors of low malignant potential (TCs) and
favourable clinical features. These results, along with
others from other authors [36,37], might suggest that
N-cadherin does not contribute to the aggressive behav-
iour of pulmonary NETs, but might serve as a marker
of neuroendocrine differentiation. Thus, differentiated
tumors might maintain N-cadherin expression that
would be lost in dedifferentiated aggressive tumours. In
line with our results, N-cadherin has been shown to be
expressed in other tumor types from neural crest/neu-
roendocrine cells origin such as astrocytomas [38],
Merkel cell carcinoma [39] and pheochromocytomas
and adrenal tumors [40] as well as in our recent study
in gastroenteropancreatic neuroendocrine tumors [41].
According to these results, the presence of N-cadherin
in pulmonary neuroendocrine tumors may be due to
neuroendocrine differentiation of the precursor cell
and does not appear to convey aggressive behavior as
demonstrated in other non-neuroendocrine malignancies.
Our results support the notion proposed by Zynger et al
[37] that N-cadherin would be a reliable immunohisto-
chemical marker for these tumors.
In our series, determination of altered complex integrity
turned out to be of help in AC vs TC discrimination. The
loss of the linear membrane pattern is a clear indicative of
complex alteration. Assessing loss of N-cadherin as well
could reinforce that discrimination. However, further stud-
ies aimed at confirming this utility are needed in order to
propose these determinations to be included in the clini-
copathological practice.
Our findings in high grade lung neuroendocrine tumors,
SCLC and LCNEC, are in favour to keep them as separate
entities. In spite of their clinical and molecular similarities,
their expression of adhesion molecules, low E-cadherin
and β-catenin cytoplasmic expression levels, as well as
high Snail1, Snail2 and Twist expression may have a value
in the differential diagnosis of SCLC and LCNEC.
The Carcinoid subtype is a quite separate entity from
the high-grade NETs and constitutes 1-2% of lung tumors
[42,43]. However, some TCs cases with favourable patho-
logic features follow an unpredictable unfavourable clinical
course. To elucidate whether some of the studied markerscould be of help in the identification of this subgroup of
patients, we assessed the impact of clinicopathological
parameters and the molecular alterations in survival
rates of TCs group. We noted that when the E-cadherin/
β-catenin complex was altered, the ten year survival rate
was 56%, versus 94% of those patients whose tumors
retained complex integrity. Loss of E-cadherin/β-catenin
integrity has been described as one of the first events pre-
ceding tumor invasion. In line with this, its evaluation has
turned to be of help in distinguishing TC cases that have
already initiated the EMT program, thus conferring more
aggressiveness and a worse prognosis. These results
highlight the potential value of the immunohistochemical
determination of E-cadherin/β-catenin complex status to
identify patients with TCs of poor prognosis. From our
perspective, this is one outstanding finding of this report.
Conclusions
In conclusion, our study suggests that loss of E-cadherin/
β-catenin complex integrity is an early event in pulmonary
NETs progression and constitutes an independent pre-
dictor of lymph node involvement and reduced survival in
pulmonary NETs, along with Snail1 and Twist expression,
mitotic index and tobacco consumption. Immunohisto-
chemical determination of the complex integrity might be
a useful molecular tool of potential clinical application in
the management of pulmonary NETs, helping in the
differential diagnosis of AC vs TCs and providing infor-
mation about prognosis, especially among patients with
TCs, identifying the subgroup with worse prognosis
despite favourable pathological features.
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